PRETREATMENT VARIATIONS IN HAEMATOLOGICAL PARAMETERS OF BREAST CANCER PATIENTS
DOI:
https://doi.org/10.22159/ijpps.2018v10i2.23669Keywords:
Breast cancer, Haemoglobin, Erythrocyte sedimentation rate, Neutrophilia, LymphocytosisAbstract
Objective: The objective of the presented study was to analyze the haematological parameters in female breast cancer (BC) patients before the start of the treatment.
Methods: The study was conducted among female BC patients, visited King Fahd Hospital (KFH), Al Ahsa, Kingdom of Saudi Arabia (KSA) from January 2013 to December 2016. A retrospective analytical study was conducted. We analyzed the relationship of haematological parameters with various stages of breast cancer before the start of any treatment. We used complete blood count (CBC) reports to analyze the haematological parameters. The mean age of the patients was 57 y (31-83 y). Most of the patients were postmenopausal (51-59 y old). We divided the patients into 4 groups according to the disease stage, i.e., stage 1 (S1) to stage 4 (S4).
Results: Among altered blood parameters, decreased haemoglobin (Hb 4.5-11 g/dl) and increased erythrocyte sedimentation rate (ESR 37–49 mm/first hour) in S1 to S4, increased neutrophil count in S3 and S4 (8.3-9.6 x103/mm3), and increased lymphocyte count (4-7.2 x103/mm3) in S1 and S2 patients were found.
Conclusion: We found significant variations in haematological parameters at different stages of breast cancer. CBC is indeed an efficient and cost-effective investigation. By managing these parameters, treatment efficacy and survival rate of BC patients may be augmented.
Downloads
References
Brown R, Kerr K, Haoudi A, Darzi A. Tackling cancer burden in the Middle East: Qatar as an example. Lancet Oncol 2012; 13:e501-8.
Radi SM. Breast cancer awareness among Saudi females in Jeddah. Asian Pac J Cancer Prev 2013;14:4307-12.
Baron Epel O, Friedman N, Lernau O. Reducing disparities in mammography-use in a multicultural population in Israel. Int J Equity Health 2009;19:8-19.
Bener A, El Ayoubi HR, Moore MA, Basha B, Joseph S, Chouchane L. Do we need to maximise the breast cancer screening awareness? Experience with an endogamous society with high fertility. Asian Pac J Cancer Prev 2009;4:599-604.
Azaiza F, Cohen M, Awad M, Daoud F. Factors associated with low screening for breast cancer in the Palestinian authority. Cancer 2010;116:4646-55.
Yousuf SA. Breast cancer awareness among Saudi nursing students. J King Abdulaziz University: Med Sci 2010;17:67-78.
Waters EA, McNeel TS, Stevens WM, Freedman AN. Use of tamoxifen and raloxifene for breast cancer chemoprevention in 2010. Breast Cancer Res Treat 2012;134:875-80.
Schroyen S, Adam S, Jerusalem G, Missotten P. Ageism and its clinical impact in oncogeriatry: state of knowledge and therapeutic leads. Clin Interventions Agin 2014;10:117-25.
Aswathy K Cherian, Poovammal E, Malathy C. Automatic feature extraction for breast density segmentation and classification. Asian J Pharm Clin Res 2017;10:111-5.
Elmore JG, Longton GM, Carney PA, Geller BM, Onega T, Tosteson AN, et al. Diagnostic concordance among pathologists interpreting breast biopsy specimens. JAMA 2015;313:1122-32.
Shaik Naseera, Gk Rajini, Saravanan M. Statistical detection of breast cancer by mammogram image. Asian J Pharm Clin Res 2017;10:227-9.
Gilkes DM. Implications of hypoxia in breast cancer metastasis to bone. Int J Mol Sci 2016;17:1669.
Boehm DU, Lebrecht A, Schmidt M, Siggelkow W, Lindner C, Litz A, et al. Prognostic impact of haemoglobin levels in breast cancer. Anticancer Res 2007;27:1223-6.
Thynne GS. Plasma carcinoembryonic antigen and erythrocyte sedimentation rate in patients with colorectal carcinoma. Med J Aust 1979;1:592-3.
Azab B, Bhatt VR, Phookan J, Murukutla S, Kohn N, Terjanian T, et al. Usefulness of the neutrophil-to-lymphocyte ratio in predicting short-and long-term mortality in breast cancer patients. Ann Surg Oncol 2012;19:217-24.
Yamanaka T, Matsumoto S, Teramukai S, Ishiwata R, Nagai Y, Fukushima M. The baseline ratio of neutrophils to lymphocytes is associated with patient prognosis in advanced gastric cancer. Oncology 2007;73:215-20.
Lee YT. Peripheral lymphocyte count and subpopulations of T and B lymphocytes in benign and malignant diseases. Surg Gynecol Obstet 1977;144:435-50.
Caine GJ, Stonelake PS, Lip GY, Kehoe ST. The hypercoagulable state of malignancy: pathogenesis and current debate. Neoplasia 2002;4:465.
Ali LO. Study effect of breast cancer on some haematological and biochemical parameters in babylon province, Iraq. IOSR-JPBS 2014;9:20-4.
Singletary SE, Allred C, Ashley P, Bassett LW, Berry D, Bland KI, et al. Revision of the American joint committee on cancer staging system for breast cancer. J Clin Oncol 2002;20:3628-36.
Bain BJ, Bates I, Laffan MA. Dacie and Lewis Practical Hematology E-Book. Elsevier Health Sciences; 2016.
Rana AP, Kaur M, Zonunsanga B, Puri A, Kuka AS. Preoperative peripheral blood count in breast carcinoma: a predictor of prognosis or a routine test. Int J Breast Cancer 2015. http://dx.doi.org/10.1155/2015/964392.
Akinbami A, Popoola A, Adediran A, Dosunmu A, Oshinaike O, Adebola P, et al. Full blood count pattern of pre-chemotherapy breast cancer patients in Lagos, Nigeria. Caspian J Intern Med 2013;4:574.
Poggiali E, De Amicis MM, Motta I. Anemia of chronic disease: a unique defect of iron recycling for many different chronic diseases. Eur J Intern Med 2014;25:12-7.
Galasko CS. Skeletal metastases. Clin Orthop Relat Res 1986;210:18-30.
Kamby C, Guldhammer B, Vejborg I, Rossing N, Dirksen H, Daugaard S, et al. The presence of tumor cells in bone marrow at the time of the first recurrence of breast cancer. Cancer 1987;60:1306-12.
Ludwig H, Fritz E, Leitgeb C, Krainer M, Kührer I, Sagaster P, et al. Erythropoietin treatment for chronic anemia of selected haematological malignancies and solid tumors. Ann Oncol 1993;4:161-7.
Bochen K, Krasowska A, Milaniuk S, Kulczynska M, Prystupa A, Dzida G. Erythrocyte sedimentation rate–an old marker with new applications. J Pre-Clin Clin Res 2011;5:50-5.
Pfeiler S, Stark K, Massberg S, Engelmann B. Propagation of thrombosis by neutrophils and extracellular nucleosome networks. Haematologica 2017;102:206-13.
Dvorak HF. Abnormalities of hemostasis in malignant disease. Hemostasis and Thrombosis. Philadelphia: JB Lippincott; 1994. p. 1238-54.
Papatestas AE, Kark AE. Peripheral lymphocyte counts in breast carcinoma: an index of immune competence. Cancer 1974;34:2014-7.
Mahmoud SM, Paish EC, Powe DG, Macmillan RD, Grainge MJ, Lee AH, et al. Tumor-infiltrating CD8+lymphocytes predict clinical outcome in breast cancer. J Clin Oncol 2011;29:1949-55.
Liu S, Lachapelle J, Leung S, Gao D, Foulkes WD, Nielsen TO. CD8+lymphocyte infiltration is an independent favourable prognostic indicator in basal-like breast cancer. Breast Cancer Res 2012;14:R48.
Ahmad SS, Akhtar K, Verma AK, Mallik AZ, Siddqui SA. Total peripheral lymphocyte count in malignant tumors: an index of prognostication. J Med Sci 2012;12:24-8.
Concha A, Cabrera T, Ruiz Cabello F, Garrido F. Can the HLA phenotype be used as a prognostic factor in breast carcinomas? Int J Cancer 1991;47:146-54.
Madjd Z, Spendlove I, Pinder SE, Ellis IO, Durrant LG. Total loss of MHC class I is an independent indicator of good prognosis in breast cancer. Int J Cancer 2005;117:248-55.
Published
How to Cite
Issue
Section
